Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

By V. Bardou, G. Arpino, R. Elledge, C. Osborne, G. Clark. Journal of Clinical Oncology, 2003

777 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007, background): “ER-negative breast carcinomas in general are associated with relatively poor prognosis [9-11]; based on published series, these patients have a 10 year relapse-free survival of 55–70%.”
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004, background): “Therefore, the ability to accurately predict tamoxifen treatment outcome should signififunctional ER pathway), are currently the best predictors of tamoxifen response in the clinical setting (Bardou et al., 2003; cantly advance the management of early-stage breast cancer.”
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients (2007, background): “Discussion Previous studies have shown survival advantages among women with hormone receptor-positive tumors relative to women with hormone receptor-negative tumors [6,9,13-16].”